Arcutis Biotherapeutics

ARQT Mid Cap

Healthcare · Biotechnology

Aktualisiert: Apr 5, 2026, 17:43 UTC

$23.63

-1.95% heute

52W: $11.86 – $31.77

52W Low: $11.86 Position: 59.1% 52W High: $31.77

🔗 Broker vergleichen

Kennzahlen

P/E Ratio

—

Kurs/Gewinn-Verhältnis

Forward P/E

18.48x

Erwartetes KGV

P/S Ratio

7.79x

Kurs/Umsatz-Verhältnis

EV/EBITDA

—

Unternehmenswert/EBITDA

Dividendenrendite

—

Jährl. Dividendenrendite

Market Cap

$2.9B

Marktkapitalisierung

Umsatzwachstum

81.5%

YoY Umsatzwachstum

Gewinnmarge

-4.29%

Nettomarge

ROE

-9.3%

Eigenkapitalrendite

Beta

1.77

Marktsensitivität

Short Interest

15.57%

% der Aktien leerverkauft

Ø Volumen

1,422,101

Durchschn. Tagesvolumen

Bewertungs-Analyse

Signal

N/A

vs. S&P 500 Ø KGV (24.7x)

Analysten-Konsens

None

8 Analysten

Ø Kursziel

$34.75

+47.06% Upside

Kursziel Spanne

$33.00 – $36.00

Über das Unternehmen

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Sektor: Healthcare Branche: Biotechnology Land: United States Mitarbeiter: 354 Börse: NMS

Trading-Daten

50-Day MA: $24.88

200-Day MA: $21.89

Volumen: 638,063

Ø Volumen: 1,422,101

Short Ratio: 11.35

Kurs/Buchwert: 15.38x

Verschuldung/EK: 60.44x

Free Cash Flow: $-15,702,750

Wo kann ich Arcutis Biotherapeutics kaufen?

Vergleiche die besten Broker — niedrige Gebühren, seriöse Anbieter, reguliert.

Broker vergleichen →